MedBiome is pleased to announce that it is attending the digital BioPharm America Digital on Sept 21-24 2020. Looking forward to new partnerships ...
Read More

Medbiome's founder recently released a new version of the metaproteomic software called MetaLab 2.0, opening the door to accurate Post-Translational Modifications profiling at the microbiome level. https://pubs.acs.org/doi/10.1021/jasms.0c00083 https://pubs.acs.org/doi/10.1021/jasms.0c00083 ...
Read More

MedBiome is pleased to announce that it will attend the digital China Bio Partnering Forum on Aug 25-27 2020. Looking forward to new partnerships with Chinese companies ...
Read More

In a recent paper in Gut Microbes the founders of MedBiome reported the effects of berberine (BBR) and 16 structural analogs on seven individual gut microbiomes using our RapidAIM technology. This article clearly illustrates that the RapidAIM technology can distinguish the effects of structurally similar compounds on individual microbiomes. This is an important milestone when selecting and optimizing compounds to target the gut microbiome ...
Read More

MedBiome's founders reported in Microbiome the development of the RapidAIM platform to screen compounds against individual microbiomes in vitro. They tested 43 compounds (including 4 antibiotics) against 5 individual microbiomes using the RapidAIM technology. The RapidAIM workflow provides insights into microbiome absolute abundance and functional responses to drugs ...
Read More

MedBiome is pleased to announce that it has licensed the iMetaLab software platform from the University of Ottawa. iMetaLab (imetalab.ca) is a leading bioinformatics software for metaproteomics data analysis. MedBiome uses the iMetaLab software in combination with the RapidAIM assay to identify Precision Microbiome Therapeutics that change the composition of the human microbiome, promote the productions of specific metabolites by the human microbiome and for the stratification of patients based on their microbiome responses. MedBiome develops Precision Microbiome Therapeutics for Inflammatory Bowel Disease, Alzheimer's Disease, Chronic kidney disease and Colorectal cancer ...
Read More

MedBiome is pleased to announce that it has exclusively licensed the RapidAIM technology from the University of Ottawa. RapidAIM is a revolutionary assay to rapidly determine the effects of compounds on individual human living microbiomes. RapidAIM fidelity maintains functional living human microbiomes in 96 well plates and allows the testing of drugs for their effects on the microbiome for up to 5 days. RapidAIM is used to identify compounds that change the composition of the human microbiome, promote the productions of specific metabolites by the human microbiome and for the stratification of patients based on their microbiome responses. MedBiome is using the RapidAIM technology to identify microbiome metabolic modulators that promote the production of specific metabolites in Inflammatory Bowel Disease, Alzheimer's Disease, Chronic kidney disease and Colorectal cancer. MedBiome also provides access to RapidAIM through partnerships ...
Read More

MedBiome, a company specializing in the development of therapeutics targeting the gut microbiome, today announced that Dr. Shane Climie has been appointed as Vice-President of Business Development. In Dr. Climie’s role as Vice President of Business Development at MedBiome Inc. he is responsible for corporate development, strategy and partnering. Dr. Climie is also President of Shane Climie & Associates which is focused on the provision of consulting services to life science companies. He is a Principal with Popper and Company, which is focused on building life science organizations by meeting the needs of entrepreneurial, life science startups and the investors that support those early stage organizations. Dr. Climie also serves as Vice President of Corporate Development at Cyclica Inc. where he supports company growth by managing corporate relationships and strategic planning. Dr. Climie has more than 25 years of R&D and business development experience in the life sciences and pharmaceutical industry. He has led research teams involved in all aspects of drug discovery and technology development, and has designed, negotiated and managed many R&D collaborations. He has extensive experience in technology evaluation, technology development and strategic planning. Dr. Climie has been a Principal at Popper and Company for 13 years ...
Read More

Looking forward to multiple partnership meetings at Bio Europe 2019 in Hamburg. >>Bio Europe 2019 ...
Read More

MedBiome's founders reported in Nature Comms. on the development of 96-well plate approach that maintains functional and compositional profiles of individual gut microbiomes. They demonstrated strong correlation between in vitro and in vivo microbiome responses to drugs ...
Read More